Trial reportJournal of aerosol medicine and pulmonary drug delivery2020
Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma.
Trial report in Journal of aerosol medicine and pulmonary drug delivery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02245672 (A Randomized, Double-blind, Double Dummy, Parallel Group Study to Determine the Local Equivalence of Multiple Doses of MGR001 to Advair Diskus Administered Via Oral Inhalation in Adult Asthma Patients), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Double Dummy, Parallel Group Study to Determine the Local Equivalence of Multiple Doses of MGR001 to Advair Diskus Administered Via Oral Inhalation in Adult Asthma Patients
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Relative Bioavailability of Inhaled Fluticasone Propionate and Salmeterol - is Population Pharmacokinetic Modelling a Relevant Alternative to a Non-Compartmental Approach?Drug design, development and therapy · 2025Trial
- Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease.Annals of internal medicine · 2023Trial
- Exploration of the potential impact of batch-to-batch variability on the establishment of pharmacokinetic bioequivalence for inhalation powder drug products.CPT: pharmacometrics & systems pharmacology · 2025Article
- Mechanistic modeling of generic orally inhaled drug products: A workshop summary report.CPT: pharmacometrics & systems pharmacology · 2023Review
- Spatial aerosol deposition correlated to anatomic feature development in 6-year-old upper airway computational models.Computers in biology and medicine · 2022Article
- Article
- Wixela Inhub: A Generic Equivalent Treatment Option for Patients with Asthma or COPD.Pulmonary therapy · 2021Review
- The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device.Pulmonary medicine · 2021Review
- Wixela Inhub: Dosing PerformanceJournal of aerosol medicine and pulmonary drug delivery · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.